Trial Profile
EverolimuS-Eluting Bioresorbable VasCular ScaffOlds Versus EveRolimus-Eluting Stents in Patients With Chronic Total Occlusion
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 27 Sep 2019
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms SCORE-CTO
- 12 Apr 2017 Status changed from recruiting to discontinued.
- 21 Sep 2016 Status changed from not yet recruiting to recruiting.
- 20 Apr 2016 New trial record